.jpg)
.png)
Although we are thousands of miles away from the National Lipid Association (NLA) headquarters and our time zone seems out of sync with scheduled committee meetings and conference calls, we appreciate the importance of working with and contributing to the NLA and strengthening not only our chapter, but the organization as a whole.
Article By:
President, Pacific Lipid Association
University of California-Irvine Medical Center
California Heart Associates
Fountain Valley, CA
Diplomate, American Board of Clinical Lipidology
A colleague recently asked us to comment on an interesting case. The patient was a 68-year-old woman hospitalized for abdominal pain and new-onset atrial fibrillation. She had a medical history significant for longstanding hypertension and non-obstructive coronary artery disease (CAD) by angiography one year prior to admission. Her home medications included simvastatin 20 mg daily and omeprazole 40 mg daily for dyspepsia.
Article By:
Oregon Health & Science University
Knight Cardiovascular Institute
Director, Cardiac MR CT Program
Center for Preventive Cardiology
Portland, OR
Diplomate, American Board of Clinical Lipidology
President, Pacific Lipid Association
University of California-Irvine Medical Center
California Heart Associates
Fountain Valley, CA
Diplomate, American Board of Clinical Lipidology
On April 18, 2016, the FDA announced retraction of prior approvals related to the combination of a statin with fenofibrate.1 This decision was prompted by the results of the ACCORD Lipid Trial, which failed to show reduction in cardiovascular events in diabetics when fenofibrate was routinely added to a statin.2 The question now is whether this failure applies to all patients or might there be a group that does benefit from a fibrate-statin combination?
Article By:
Director, Advance Lipid Management Program
Tyler Heart Institute, Community Hospital of Monterey Peninsula
Monterey, CA
Diplomate, American Board of Clinical Lipidology
Introduction
Article By:
Director of Nutrition
University of California Irvine Preventive Cardiology Program
Associate Clinical Professor of Medicine (Cardiology)
University of California Irvine, College of Medicine
Diplomate, Accreditation Council for Clinical Lipidology
Wellness Center Director/Clinical Assistant Professor
Division of Health Sciences
Idaho State University
Diplomate, Accreditation Council for Clinical Lipidology
Article By:
Are you interested in preventive care? How about lifestyle focus, medical management, multi-specialty collaboration, an evidence-based approach, genetics and the related usage of technology? Then being credentialed as a clinical lipid specialist (CLS) should be in your future.
Article By:
Nurse Practitioner
The Polyclinic
Seattle, WA
Diplomate, Accreditation Council for Clinical Lipidology
Medical literature is replete with the use of more complex statistics these days, and many of our practice guidelines require more and more rigorously conducted studies with sophisticated statistics to be considered. It is important that clinical lipid specialists and others in the field of preventive cardiology understand and be wary of some key issues in the interpretation of different studies.
Article By:
Professor and Director
Heart Disease Prevention Program
Division of Cardiology
University of California, Irvine
Irvine, CA
The word “pleiotropy” is derived from the Greek word pleon, which means “more,” and tropos, which means “way” and refers to when a gene produces two or more unrelated pleiotropic traits. The term “statin pleiotropy” has been used to refer to mechanisms independent of cholesterollowering effects. Statins are indicated for both primary and secondary prevention of coronary heart disease.
Article By:
Intermountain Heart Institute
Intermountain Medical Center
Salt Lake City, UT
Director
California Cardiovascular Institute
Fresno, CA
Diplomate, American Board of Clinical Lipidology
The Very High ASCVD Risk Category
Article By:
Clinical Professor of Medicine, Division of Endocrinology
UC Irvine, School of Medicine, Irvine, CA
Co-Director, Diabetes Outpatient Clinic
UCI Medical Center, Orange, CA
Private Practice: Director & Principal Investigator
Diabetes / Lipid Management & Research Center
Huntington Beach, CA
Diplomate, American Board of Clinical Lipidology
President-Elect, Pacific Lipid Association
Private Practice: Endocrinology, Diabetes, Metabolism, Internal Medicine
Medical Director & Principal Investigator
Metabolic Institute of America
Tarzana, CA
In Greek mythology Sisyphus was the king of Ephyra (now known as Corinth). He was punished for his self-aggrandizing craftiness and deceitfulness by being forced to roll an immense boulder up a hill, only to watch it come back to hit him, repeating this action for eternity.”1
Article By:
Clinical Associate Professor of Medicine
University of Pennsylvania
Internal Medicine and Preventive Cardiology
University of Pennsylvania Health System
Philadelphia, PA
Diplomate, American Board of Clinical Lipidology